期刊
EUROPEAN UROLOGY OPEN SCIENCE
卷 27, 期 -, 页码 29-32出版社
ELSEVIER
DOI: 10.1016/j.euros.2021.02.006
关键词
Non-muscle-invasive bladder cancer; Luminal subtype; FGFR3; ERBB2; KRT20; Metastasis; Death
Transitional cell carcinoma of the bladder is a common malignancy with high recurrence and progression rates, and current therapy strategies are mainly based on clinical and histopathological findings. Studies on molecular subtypes of bladder cancer are ongoing to identify potential therapeutic targets.
Transitional cell carcinoma of the bladder is a common malignancy with an estimated 549 393 new cases occurring in 2018 alone. Both non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) show high recurrence and progression rates, and therefore impose a great burden on patients and health care systems. Current risk stratification and therapy strategies are predominantly based on clinical and histopathological findings for tumor stage and grade. The chemoresistance and metastasis of low-grade tumors suggest an incomplete understanding of disease mechanisms, despite numerous studies on differentiating molecular subtypes of bladder cancer to identify tumor drivers and potential therapeutic targets. We present a highly unusual course for a low-grade bladder tumor leading to metastasis and death, for which we used postmortem histopathological and molecular analyses to evaluate targetable alterations in key signaling pathways driving the underlying tumor biology. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据